Cover Image
市場調查報告書

氣喘治療藥的全球市場:2016年∼2020年

Global Asthma Therapeutics Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 365938
出版日期 內容資訊 英文 110 Pages
訂單完成後即時交付
價格
Back to Top
氣喘治療藥的全球市場:2016年∼2020年 Global Asthma Therapeutics Market 2016-2020
出版日期: 2016年07月27日 內容資訊: 英文 110 Pages
簡介

過敏性鼻炎的增加是過敏性氣喘增加的主要原因,為了治療氣喘便促進了免疫療法之研究開發。全球氣喘治療藥市場在2016年∼2020年這段期間,預測將以年複合成長率(CAGR)4.31%的速度成長。

本報告提供全球氣喘治療藥市場相關調查分析,提供您市場概要,各市場區隔考察,各地區考察,推動市場的要素,主要企業等概括性分析、彙整資料。

第1章 摘要整理

第2章 報告的範圍

第3章 市場調查的方法

  • 調查方法
  • 經濟指標

第4章 簡介

第5章 開發平台的組合

第6章 市場的狀況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 氣喘治療藥主要的購買標準

第8章 氣喘治療藥的全球市場:治療的種類

  • 預防藥
  • 速效藥
  • 其他

第9章 氣喘治療藥的全球市場:藥物類別

  • 聯合治療
  • 支氣管擴張劑
  • 免疫抑制劑
  • 白三烯拮抗劑
  • 肥大細胞穩定劑

第10章 市場區隔:給藥途徑

  • 吸入
  • 非口服
  • 口服

第11章 氣喘治療藥的藥物輸送設備市場

  • 市場概要
  • 市場區隔:產品種類

第12章 氣喘治療藥的全球市場:各地區

  • 全球氣喘治療藥市場:各地區:2015年∼2020年
  • 南北美洲
  • 歐洲/中東/非洲
  • 亞太地區

第13章 氣喘治療藥的全球市場:促進要素

  • mAbs的巨大市場潛力
  • 將學名藥影響壓到最小的新產品認證
  • 由於環境污染造成過敏疾病的增加

第14章 促進要素的影響

第15章 氣喘治療藥的全球市場:課題

第16章 促進要素與課題的影響

第17章 氣喘治療藥的全球市場:趨勢

  • 藥物輸送的創新技術
  • 免疫療法的引進增加
  • 由糖皮質激素,腎上腺素受體轉變到以免疫/發炎系目標
  • 線上行銷服務的增加
  • 居家醫療設備的利用增加

第18章 供應商狀況

第19章 主要供應商分析

第20章 附錄

第21章 Technavio的其他的報告

目錄
Product Code: IRTNTR10076

About Asthma Therapeutics

Increasing allergic rhinitis is a major factor for allergic asthma leading to increase in research for the development of allergic immunotherapies for the treatment of asthma. The global asthma therapeutics market will observe a moderate growth during the forecast period because of loss of patent exclusivity of the major drugs, allowing the entry of generics into the market. This will lead to the erosion of the market share of the major asthma drugs. However, the presence of late-stage pipeline molecules will drive the market. An increase in the prevalence of asthma and the use of combination drugs will drive the growth of the market during the forecast period.

Technavio's analysts forecast the global asthma therapeutics market to grow at a CAGR of 4.31% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global asthma therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the sales of brand-name, generic, and off-label drugs used for the prevention and treatment of asthma. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Asthma Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AstraZeneca
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • GSK
  • Merck

Other Prominent Vendors

  • ALK-Abello
  • Amgen
  • Array BioPharma
  • Asmacure
  • Astellas Pharma
  • Atopix Therapeutics
  • Axikin Pharmaceuticals
  • Chiesi Farmaceutici
  • Dynavax Technologies Corp.
  • Horizon Pharma
  • Hovione Scientia
  • Invion
  • Ivax
  • Kissei Pharmaceutical
  • Kyowa Hakko Kirin
  • MediciNova
  • Mitsubishi Tanabe Pharma Corporation
  • Mundipharma
  • Nycomed
  • Oxagen Limited
  • Palobiofarma
  • Pearl Therapeutics
  • Pharmaking
  • Pharmaxis
  • Pulmagen Therapeutics
  • Regeneron Pharmaceuticals
  • Revalesio
  • RSPR Pharma AB
  • SAMA Pharmaceuticals
  • Sanofi
  • Skyepharma
  • SolAeroMed
  • Stallergenes
  • Sterna Biologicals
  • Synairgen
  • Theron Pharmaceuticals
  • UCB Pharma
  • Vectura
  • Verona Pharma
  • Whanin Pharmaceutical Company

Market driver

  • Huge market potential for mAbs
  • For a full, detailed list, view our report

Market challenge

  • Increased preference for CAM
  • For a full, detailed list, view our report

Market trend

  • Innovative technologies for drug delivery
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Breakthrough in asthma research
  • Asthma: An overview

PART 05: Pipeline portfolio

PART 06: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 07: Key buying criteria for asthma drugs

PART 08: Market segmentation by type of treatment

  • Preventive medications
  • Quick-relief medications
  • Others

PART 09: Market segmentation by drug class

  • Combination therapies
  • Bronchodilators
  • Immunosuppressants
  • Leukotriene antagonists
  • Mast cell stabilizers

PART 10: Segmentation by route of administration

  • Inhalation
  • Parenteral
  • Oral

PART 11: Drug delivery devices market for asthma drugs

  • Market overview
  • Market segmentation by product type

PART 12: Geographical segmentation

  • Global asthma therapeutics market by geography 2015-2020
  • Asthma therapeutics market in Americas
  • Asthma therapeutics market in EMEA
  • Asthma therapeutics market in APAC

PART 13: Market drivers

  • Huge market potential for mAbs
  • New product approvals minimizing the impact of generic erosion
  • Increasing rate of allergies due to environmental pollution

PART 14: Impact of drivers

PART 15: Market challenges

  • Increased preference for CAM
  • Poor patient adherence toward controller medications
  • Presence of different phenotypes of asthma leading to prescription errors

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Innovative technologies for drug delivery
  • Growing adoption of immunotherapies
  • Shift toward immune/inflammatory system targets from glucocorticoid and adrenergic receptors
  • Increase in online marketing services
  • Growing use of home healthcare devices

PART 18: Vendor landscape

  • Competitive scenario
  • Key news

PART 19: Key vendor analysis

  • AstraZeneca
  • Boehringer Ingelheim
  • F. Hoffmann-La Roche
  • GSK
  • Merck
  • Other prominent vendors

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Breakthrough in asthma research
  • Exhibit 03: Major diagnostic procedures for asthma
  • Exhibit 04: Percentage share of pipeline molecules based on stage of development
  • Exhibit 05: Pipeline portfolio: Global asthma therapeutics market
  • Exhibit 06: Global asthma drugs market: Market overview 2015
  • Exhibit 07: Global asthma therapeutics market 2015-2020 ($ billions)
  • Exhibit 08: Global asthma drugs market snapshot: Developed and emerging markets 2015
  • Exhibit 09: Global asthma therapeutics market: Key parameters driving the market growth 2015
  • Exhibit 10: Five forces analysis
  • Exhibit 11: Key buying criteria for asthma drugs
  • Exhibit 12: Global asthma therapeutics market: Key parameters importance
  • Exhibit 13: Impact of key customer segments on market
  • Exhibit 14: Segmentation of asthma drugs based on type of treatment
  • Exhibit 15: Segmentation of asthma drugs based on drug class
  • Exhibit 16: Percentage share of global asthma therapeutics by drug class based on revenue 2015
  • Exhibit 17: Global asthma therapeutics market: Drug class segmentation growth cycle analysis 2015
  • Exhibit 18: Combination therapies market in global asthma therapeutics market 2015-2020 ($ billions)
  • Exhibit 19: Bronchodilators market in global asthma therapeutics market 2015-2020 ($ billions)
  • Exhibit 20: Percentage share of allergy immunotherapies and steroids in global immunosuppressants market 2015
  • Exhibit 21: Immunosuppressants market in global asthma therapeutics market 2015-2020 ($ billions)
  • Exhibit 22: Leukotriene antagonists market in global asthma therapeutics market 2015-2020 ($ billions)
  • Exhibit 23: Mast cell stabilizers market in global asthma therapeutics market 2015-2020 ($ billions)
  • Exhibit 24: Segmentation of global asthma therapeutics market by route of administration
  • Exhibit 25: Global asthma drug delivery devices market 2015-2020 ($ millions)
  • Exhibit 26: Global asthma drug delivery devices market segmentation by product type
  • Exhibit 27: Percentage share of global asthma drug delivery devices by type 2015
  • Exhibit 28: Percentage share of inhalers in global asthma drug delivery devices market 2015
  • Exhibit 29: Inhalers market in global asthma drug-delivery devices market 2015-2020 ($ millions)
  • Exhibit 30: Percentage share of nebulizers in global asthma drug delivery devices market 2015
  • Exhibit 31: Nebulizers market in global asthma drug-delivery devices market 2015-2020 ($ millions)
  • Exhibit 32: Global asthma therapeutics market by geography 2015-2020
  • Exhibit 33: Percentage share of global asthma therapeutics market by geography 2015 and 2020
  • Exhibit 34: Global asthma therapeutics market segmentation by geography 2015-2020 ($ billions)
  • Exhibit 35: Global share of asthma therapeutics market by geography 2015
  • Exhibit 36: Global asthma therapeutics market: Country analysis based on revenue and growth rate
  • Exhibit 37: Impact of ACA act on asthma therapeutics market
  • Exhibit 38: Asthma therapeutics market in Americas 2015-2020 ($ billions)
  • Exhibit 39: Asthma therapeutics market: PEST analysis
  • Exhibit 40: Prevalence of asthma in major countries of EMEA
  • Exhibit 41: Asthma therapeutics market in EMEA 2015-2020 ($ billions)
  • Exhibit 42: Asthma therapeutics market in EMEA: PEST analysis
  • Exhibit 43: Asthma therapeutics market in APAC 2015-2020 ($ billions)
  • Exhibit 44: Asthma therapeutics market: PEST analysis
  • Exhibit 45: mAbs approved for treatment of asthma
  • Exhibit 46: mAbs under development for treatment of asthma
  • Exhibit 47: Impact of drivers
  • Exhibit 48: Use of CAM therapies among individuals in US
  • Exhibit 49: Impact of drivers and challenges
  • Exhibit 50: Market share of major vendors based on asthma therapeutics revenue 2015
  • Exhibit 51: Competitive scenario of global asthma therapeutics market vendors 2015-2020
  • Exhibit 52: Geographical presence of key vendors
  • Exhibit 53: AstraZeneca: YoY revenue and growth rate of Symbicort 2013-2015 ($ billions)
  • Exhibit 54: AstraZeneca: Geographical segmentation of Symbicort 2015
  • Exhibit 55: AstraZeneca: YoY revenue and growth rate of Pulmicort 2013-2015 ($ millions)
  • Exhibit 56: AstraZeneca: Geographic segmentation of Pulmicort 2015
  • Exhibit 57: AstraZeneca: Metrics analysis
  • Exhibit 58: Boehringer Ingelheim: YoY revenue and growth rate of Spiriva 2013-2015 ($ billions)
  • Exhibit 59: Boehringer Ingelheim: Metrics analysis
  • Exhibit 60: F. Hoffmann-La Roche: YoY revenue and growth rate of Xolair 2012-2014 ($ millions)
  • Exhibit 61: F. Hoffmann-La Roche: Metrics analysis
  • Exhibit 62: GSK: YoY revenue and growth rate of Seretide/Advair 2013-2015 ($ billions)
  • Exhibit 63: Geographical segmentation of Seretide/Advair 2015
  • Exhibit 64: GSK: YoY revenue and growth rate of Flixotide/Flovent 2013-2015 ($ billions)
  • Exhibit 65: GSK: Geographical segmentation of Flixotide/Flovent 2015
  • Exhibit 66: GSK: YoY revenue and growth rate of Ventolin 2013-2015 ($ billions)
  • Exhibit 67: GSK: Geographical segmentation of Ventolin 2015
  • Exhibit 68: GSK: YoY growth and revenue of Relvar/Breo Ellipta 2014-2015 ($ millions)
  • Exhibit 69: GSK: Geographical segmentation of Relvar/Breo Ellipta 2015
  • Exhibit 70: GSK: Metrics analysis
  • Exhibit 71: Merck: YoY growth and revenue of Singulair 2013-2015 ($ millions)
  • Exhibit 72: Merck: YoY growth and revenue of Dulera 2013-2015 ($ millions)
  • Exhibit 73: Merck: Metrics analysis0
Back to Top